Pharmacogenomic Testing: Clinical Trials

30 trials of Pharmacogenomic Testing, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

19 completed, 4 terminated, 3 active not recruiting, 2 unknown. 30 Phase 2, 3 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 230Completed 19, Terminated 4, Active not recruiting 3, Unknown 2, Withdrawn 2
Phase 13Completed 2, Active not recruiting 1
Phase 31Terminated 1

Follow Pharmacogenomic Testing: new trials by email Literature Review of Pharmacogenomic Testing trials Research Report on Pharmacogenomic Testing

Trials (filtered) newest first · largest first

All 30 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma
Cabozantinib, Pharmacogenomic Study, Pharmacokinetic Study - Metastatic Carcinoma in the Adrenal Cortex, Stage III Adrenal Cortex Carcinoma AJCC v8
Phase 2CompletedM.D. Anderson Cancer Center182018-02-262024-12-10
HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma
HIF-2alpha Inhibitor PT2385, Pharmacological Study, Laboratory Biomarker Analysis - Recurrent Glioblastoma
Phase 2CompletedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins242017-09-142022-05-09
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Laboratory Biomarker Analysis, Nivolumab, Pharmacogenomic Study - Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)32017-02-232025-03-14
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
Ibrutinib, Laboratory Biomarker Analysis, Pharmacogenomic Study - Metastatic Melanoma, Recurrent Cutaneous Melanoma
Phase 2CompletedNational Cancer Institute (NCI)182016-12-162026-08-11
Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors
Carvedilol, Laboratory Biomarker Analysis, Pharmacogenomic Study - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Phase 2CompletedChildren's Oncology Group1962016-04-042025-04-23
LCI-NOS-PAIN-001: A Prospective, Pharmacogenomic-Driven Study of Pain Management in Oncology Outpatients
Pharmacogenomic Testing - Malignant Tumor of Ill-defined Site
Phase 2TerminatedWake Forest University Health Sciences752015-09-012022-11-03
Pembrolizumab in Treating Patients With Malignant Mesothelioma
Pembrolizumab, Laboratory Biomarker Analysis, Pharmacogenomic Study - Biphasic Mesothelioma, Epithelioid Mesothelioma
Phase 2CompletedUniversity of Chicago652015-03-312026-05-08
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
selumetinib, Akt inhibitor MK2206, laboratory biomarker analysis - Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder
Phase 2WithdrawnNational Cancer Institute (NCI)2013-01-012014-09-09
Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
bortezomib, rituximab, laboratory biomarker analysis - Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma
Phase 2CompletedCity of Hope Medical Center232011-10-032023-07-27
Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy
pazopanib hydrochloride, laboratory biomarker analysis, pharmacogenomic studies - Lung Cancer
Phase 2 / Phase 3TerminatedEuropean Organisation for Research and Treatment of Cancer - EORTC1022011-07-012018-07-12
Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck
erlotinib hydrochloride, intensity-modulated radiation therapy, pharmacogenomic studies - Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx
Phase 2TerminatedCase Comprehensive Cancer Center22011-01-012020-05-12
Vismodegib in Treating Patients With Advanced Chondrosarcomas
Laboratory Biomarker Analysis, Pharmacogenomic Study, Vismodegib - Clear Cell Chondrosarcoma, Dedifferentiated Chondrosarcoma
Phase 2Active not recruitingNational Cancer Institute (NCI)452010-12-212026-08-13
Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors
Tamoxifen Citrate, Placebo, Digital mammography - Breast Cancer
Phase 2Active not recruitingUniversity of Alabama at Birmingham842010-09-012026-01-05
Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer
FOLFIRI regimen, fluorouracil, irinotecan hydrochloride - Colorectal Cancer
Phase 2CompletedCardiff University1112010-04-012014-07-08
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study - Metastatic Malignant Solid Neoplasm, Recurrent Fallopian Tube Carcinoma
Phase 1 / Phase 2Active not recruitingNational Cancer Institute (NCI)882009-11-032026-09-14
Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye
bevacizumab, temozolomide, polymorphism analysis - Intraocular Melanoma
Phase 2UnknownInstitut Curie352009-10-012013-08-26
Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery
FOLFIRI regimen, fluorouracil, irinotecan hydrochloride - Colorectal Cancer, Metastatic Cancer
Phase 2WithdrawnFederation Francophone de Cancerologie Digestive2009-04-012022-08-30
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
saracatinib, pharmacogenomic studies, pharmacological study - Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Phase 2CompletedNational Cancer Institute (NCI)192008-10-012019-04-02
Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer
abiraterone acetate, laboratory biomarker analysis, pharmacogenomic studies - Breast Cancer
Phase 1 / Phase 2CompletedCancer Research UK772008-10-012017-01-26
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
tamoxifen citrate, gene expression analysis, pharmacogenomic studies - Breast Cancer, Menopausal Symptoms
Phase 2CompletedUNC Lineberger Comprehensive Cancer Center5012008-06-182017-08-01

Showing 20 of 30. Sign in to see all of them.

Conditions studied

Breast Neoplasms (5)  ·  Carcinoma, Non-Small-Cell Lung (4)  ·  Colorectal Neoplasms (3)  ·  Rectal Neoplasms (3)  ·  Adenocarcinoma of Lung (2)  ·  Adenocarcinoma, Bronchiolo-Alveolar (2)  ·  Colonic Neoplasms (2)  ·  Lymphoma (2)  ·  Lymphoma, Mantle-Cell (2)  ·  Melanoma (2)  ·  Neoplasm Metastasis (2)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Squamous Cell Carcinoma of Head and Neck (2)  ·  Adenocarcinoma, Follicular (1)  ·  Adrenal Cortex Neoplasms (1)

Sponsors

National Cancer Institute (NCI) (11)  ·  University of Nebraska (2)  ·  Wake Forest University Health Sciences (2)  ·  Cancer Research UK (1)  ·  Cardiff University (1)  ·  Case Comprehensive Cancer Center (1)  ·  Children's Oncology Group (1)  ·  City of Hope Medical Center (1)  ·  European Organisation for Research and Treatment of Cancer - EORTC (1)  ·  Federation Francophone de Cancerologie Digestive (1)  ·  Institut Cancerologie de l'Ouest (1)  ·  Institut Curie (1)  ·  M.D. Anderson Cancer Center (1)  ·  Mayo Clinic (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)

Countries

United States (21)  ·  France (5)  ·  United Kingdom (3)  ·  Australia (2)  ·  Canada (2)  ·  Belgium (1)  ·  Egypt (1)  ·  Germany (1)  ·  Greece (1)  ·  Netherlands (1)  ·  New Zealand (1)  ·  Singapore (1)  ·  Slovenia (1)

Top investigators

Andrea E Wahner Hendrickson (1)  ·  Anna Pavlick (1)  ·  Anne Thomas, MD (1)  ·  Antoine Italiano (1)  ·  Charles Rudin (1)  ·  Elizabeth C. Reed, MD (1)  ·  Erick Gamelin, MD (1)  ·  Hedy Kindler (1)  ·  Jai Patel, PharmD (1)  ·  James N. Ingle, MD (1)  ·  Johann Sebastian de Bono, MD (1)  ·  Julian R. Molina, MD, PhD (1)  ·  Lee Ratner (1)  ·  Lisa A. Carey, MD (1)  ·  Marcel Devetten, MD (1)

Results publications

PMID 20098694, PMID 24100924, PMID 24170610, PMID 27716152, PMID 29954415, PMID 31467059, PMID 33661190, PMID 34414777, PMID 37864646, PMID 38608694

NIH funding

N01CM62201 (2), P30CA014599 (2), P30CA015083 (2), P30CA036727 (2), UM1CA186686 (2), UM1CA186704 (2), N01CM00070 (1), N01CM17103 (1), N01CM62202 (1), N01CM62205 (1), N01CM62209 (1), P30CA016086 (1), P50CA136393 (1), R01CA140245 (1), R01CA196854 (1)